The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica

Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica

January 1, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—A randomized efficacy and safety study showed that tocilizumab is superior to placebo for attaining sustained glucocorticoid-free remission in patients with new-onset polymyalgia rheumatica (PMR) receiving background glucocorticoid treatment. Michael Bonelli, MD, associate professor of medicine in the Division of Rheumatology at the Medical University of Vienna, Austria, presented these data during ACR Convergence 2021, held Nov. 3–9.1

You Might Also Like
  • Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis
  • Polymyalgia Rheumatica
  • Polymyalgia Rheumatica Misdiagnosis Results in Positive Outcome
Explore This Issue
January 2022
Also By This Author
  • Biosimilar for Infliximab Launched in Europe

PMR is a musculoskeletal disorder with an unknown cause. Its main symptoms are muscle pain and stiffness. Other symptoms include fever, weakness and weight loss. Genetics and/or environmental factors may be involved in its development. In some cases, PMR develops overnight, but it can also have a more gradual onset. Symptoms are usually worse in the morning and can develop quickly. The disease occurs more commonly in women than men, as well as in people of Scandinavian or Northern European heritage, and almost always in patients older than 50 years of age. The average age of symptom onset is 70 years.2,3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

PMR is often misdiagnosed. It does not cause swollen joints, so it can be difficult to recognize. It occurs in approximately 50% of patients diagnosed with giant cell artertis.

PMR rapidly responds to low doses of glucocorticoids, but may recur as the dose is tapered. Continued glucocorticoid treatment may lead to significant adverse effects. A need exists for effective, steroid-sparing agents to treat PMR.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Study

Dr. Bonelli and colleagues performed this randomized, double-blind, multi-center, phase 2/3 study in patients with new-onset PMR from three Austrian centers. In the study, patients received either 162 mg of subcutaneous tocilizumab or matching placebo in a 1:1 ratio weekly for 16 weeks. Additionally, all patients received a starting dose of 20 mg of prednisone accompanied by a rapid taper schedule over 11 weeks.

The primary end point was the proportion of patients in glucocorticoid-free remission at week 16. After week 16, follow-up was obtained up to week 24 to assess sustained efficacy and safety (NCT03263715 PMR-SPARE).4 Secondary end points included time to first relapse and cumulative glucocorticoid dose at weeks 16 and 24.

Results: Thirty-six patients were randomly assigned to receive either tocilizumab (n=19) or placebo (n=17). At week 16, glucocorticoid-free remission was achieved by 12 (63.2%) of the patients treated with tocilizumab compared with two (11.8%) of the patients who received placebo. This finding corresponds to an odds ratio of 12.9 (95 % confidence interval [CI], 2.2 to 73.6) in favor of tocilizumab (P=0.002 by Fisher’s exact test).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Issue: January 2022

You Might Also Like:
  • Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis
  • Polymyalgia Rheumatica
  • Polymyalgia Rheumatica Misdiagnosis Results in Positive Outcome
  • Letters: Don’t Forget Lyme Disease When Considering Polymyalgia Rheumatica

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)